The Calcimimetic Cinacalcet Normalizes Serum Calcium in Subjects with Primary Hyperparathyroidism

摘要: Calcimimetics increase the sensitivity of calcium-sensing receptor (CaR) to circulating serum calcium, reducing secretion PTH and calcium concentration. We evaluated calcimimetic cinacalcet, a novel therapy for management primary hyperparathyroidism. In this randomized, double-blind, dose-finding study, patients (n = 22) with hyperparathyroidism were given cinacalcet (30, 40, or 50 mg) placebo twice daily 15 d observed an additional 7 d. Serum plasma PTH, 24-h fasting urine measured. Baseline mean was 10.6 mg/dl combined cinacalcet-treated (normal range, 8.4-10.3 mg/dl), compared 10.4 group. Mean at baseline 102 pg/ml 10-65 pg/ml) patients, 100 in normalized after second dose on 1 remained normal through all groups. Maximum decreases over 50% occurred 2-4 h dosing The creatinine ratios similar This study demonstrates that safely lowered concentrations without increasing urinary excretion subjects, indicating potential benefit as medical treatment